Pharmaceutical Go-To-Market and Launch Strategy
Most launch plans fail in the gap between the global brand strategy and what a local market will pay for, prescribe and reimburse. Egypt is not a scaled-down European market — it has its own pricing mechanics, tender structures, insurance transition and physician economics. We plan against those, not around them.
In short
Hibridge builds and executes go-to-market plans for pharmaceutical products entering Egypt and MENA markets. Work covers market and competitor assessment, pricing and access positioning, segmentation and targeting, channel mix, field-force enablement, launch-readiness milestones, and the first-year performance tracking that tells you whether the plan is holding.
What we do
Launch sequencing built around what the market will actually reimburse.
Market and opportunity assessment
Epidemiology, treatment pathway mapping, competitor share and the realistic addressable patient population, sized rather than asserted.
Pricing and access positioning
Reference pricing exposure, tender and public procurement dynamics, and positioning against the Universal Health Insurance rollout as it reaches each governorate.
Segmentation and targeting
Prescriber segmentation by potential and behaviour, account prioritisation, and a call plan the field force can actually run.
Launch readiness
Milestone plan from pre-launch through to first-year review, with clear gates and named owners on each.
Field-force enablement
Detail aids, objection handling, training and rehearsal — all pre-cleared before the first cycle meeting.
Launch performance tracking
A defined metric set agreed before launch, reported against forecast, so course correction happens in month three rather than month eleven.
Approach
How we build a launch
01
Diagnose
Where the product genuinely wins, and against whom. Evidence over assumption.
02
Position
Access, pricing and clinical narrative resolved as one decision, not three.
03
Sequence
What happens in which month, who owns it, and what has to be true for the next step to start.
04
Execute and correct
Delivery against the plan with a monthly read on the agreed metrics.
Why it matters
Launch underperformance is not an edge case. It is the base rate. Half of the 2023 US launch class came in below its own pre-launch forecast, and first-time launchers do materially worse than established players.
50%
Trinity Life Sciences ·
20–30%
McKinsey & Company ·
EGP 422bn
Egyptian Drug Authority ·
Sources
Every figure on this page is attributed to its original publisher. Where a figure is organiser-reported or secondary, we say so.
Frequently asked questions
- Do you work on pre-launch, or only at launch?
- Pre-launch is where the decisions with the largest downstream cost are made — pricing exposure, evidence gaps, KOL sequencing. Engaging twelve to eighteen months out is normal.
- Can you work alongside our global brand team?
- Yes, and usually the point of the engagement is translation: taking a global strategy and resolving it against Egyptian pricing, tender and reimbursement reality without breaking brand consistency.
- Do you cover generics and biosimilars?
- Yes. The commercial logic differs sharply from innovator launches — tender positioning and cost-of-goods discipline matter more than share of voice — and we plan accordingly.
Related services
Conference & Event Management
Congresses, symposia and advisory boards, run to pharma standards.
Conferences & EventsPharmaceutical Marketing
HCP and patient programmes that survive review and move prescribing.
MarketingBranding & Brand Strategy
Identity systems that hold across markets, languages and review.
BrandingTell us what you are working on.
A launch, a congress, a portfolio that is not performing, or a compliance process that has become the bottleneck. We reply within one business day.